TEOSYAL RHA 2 2x1ml – 23 mg/mL cross-linked hyaluronic acid with 0.3% lidocaine
TEOSYAL RHA 2 is a CE-marked Class III injectable manufactured by Teoxane. It belongs to the dermal filler class: a cross-linked hyaluronic acid gel that corrects by occupying volume, and is progressively resorbed. The full Teosyal range is stocked alongside it.
Placement is not fixed to one plane. Teoxane names the dermis, the subcutaneous layer, the supraperiosteum, and the subdermis or submucosa of the red lip, chosen according to the area being treated. That is why a single product carries an indication spanning the upper face, the periorbital region, the midface and the perioral area.
Choose RHA 2 when the objective is correction across expressive areas rather than projection in one of them, and when the same syringe needs to serve forehead, nasolabial fold and perioral work in a single session.
Product overview
| Mode of correction | Volume replacement by a cross-linked hyaluronic acid gel; biodegradable, progressively resorbed |
|---|---|
| Manufacturer indication | Correction of facial wrinkles and skin creases and augmentation of facial tissue volume, across the upper face, periorbital, midface and perioral regions |
| Placement | Dermis, subcutaneous, supraperiosteal, or subdermis and submucosa of the red lips, depending on the area |
| Onset | Immediate; the gel occupies volume on placement |
| Estimated duration | 12 to 18 months, per Teoxane; dependent on skin type, area, volume placed and patient physiology |
| Patient profile | Adults with wrinkles and creases in mobile facial areas |
Specification
| Product type | Cross-linked hyaluronic acid dermal filler; sterile, transparent, non-pyrogenic viscoelastic injectable gel |
|---|---|
| Manufacturer | Teoxane SA |
| Regulatory status | CE-marked Class III medical device |
| Active substance | Hyaluronic acid, 23 mg/mL, non-animal origin, mean molecular weight above 1 million Dalton |
| Crosslinking | BDDE; degree of crosslinking below 5% by NMR; residual BDDE below 1 ppm |
| Anaesthetic | Lidocaine hydrochloride, 0.3% by mass |
| Buffer | Phosphate buffer pH 7.3 |
| Storage | 2 to 25 degrees Celsius, away from direct sunlight |
| Intended users | Trained healthcare professionals qualified or accredited under national law |
How it works
Hyaluronic acid is a constituent of the dermal extracellular matrix whose content falls with age. RHA 2 replaces volume mechanically: the gel occupies space at the plane where it is placed, corrects wrinkles and cutaneous depressions, and is progressively resorbed. Teoxane reports an aesthetic improvement of the treated area in 70 to 100% of patients across its clinical study programme, and patient-reported satisfaction consistently above 70% up to six months after the first injection.
One syringe, four planes of placement. The region decides the depth, not the product.
Treatment areas
| Region | Areas named in the instructions for use |
|---|---|
| Upper face | Forehead lines, forehead depression, glabellar lines, temples |
| Periorbital | Eyebrows, crow’s feet |
| Midface | Nasolabial folds, smile lines and accordion lines |
| Perioral | Perioral rhytids, lips including the philtrum, marionette lines, oral commissures |
Volume per point and per session follows the instructions for use. Teoxane states a maximum of 6 mL per session, and recommends the smallest workable volume in sensitive indications, with a maximum of 2 mL for the lips.
Other fillers indexed for the same objectives: moderate wrinkles, furrows and folds, perioral area.
Administration
Each syringe is supplied with two sterile 30G 1/2″ needles from Teoxane-approved suppliers. A blunt 25G cannula may be used instead; Teoxane has verified compatibility with the TSK 25G/50 mm cannula, with an entry point made using a sharp needle of appropriate size. Compatible cannulas and needles are stocked separately. The instructions for use warn against contact between TEOSYAL gels and quaternary ammonium salts such as benzalkonium chloride.
Safety profile
Common reactions at the injection site (at or above 1 in 100), usually mild and self-resolving: pain, tenderness, erythema, bruising, oedema, induration, papules and itching. Less common (between 1 in 1,000 and 1 in 100): discoloration, inflammatory reactions, infection, temporary loss of sensitivity or paraesthesia, allergic reactions, nodules and implant migration.
Injection into or close to a blood vessel may lead to embolisation, vascular occlusion, ischaemia and skin or tissue necrosis. Teoxane reports that although such events are extremely rare, the most serious cases of vascular occlusion may cause temporary or permanent vision impairment, or cerebral ischaemia or haemorrhage leading to stroke, which can be fatal. That risk is higher when injecting in the nose or the glabella – relevant here, because glabellar lines are among the stated indications. If skin whitening, marbling, pain or numbness occurs at any point during the procedure, the injection is stopped.
The product contains lidocaine, which may produce a positive result in a doping test.
Contraindications
- Cutaneous disorders, inflammation or infection at or near the treatment site
- Known hypersensitivity to hyaluronic acid, or a history of severe allergy or anaphylactic shock
- Autoimmune disease
- Pregnancy, breastfeeding, or patients under 18
- Known hypersensitivity to lidocaine or amide local anaesthetics
- Cardiac disease, or treatment for cardiac disease with beta blockers
- Hepatocellular insufficiency or treatment for liver disease
- Epilepsy or porphyria
Teoxane also states that the product is not to be injected into the epidermis, into or close to a blood vessel or nerve, or at depths other than those described in the dosage section, and is not to be combined with peeling, laser or ultrasound-based procedures. This summary does not replace the product-specific instructions for use.
Frequently asked questions
How does RHA 2 differ from TEOSYAL PureSense gels?
By crosslinking degree and by breadth of indication. Teoxane states below 5% crosslinking for RHA 2 against below 10% for the PureSense range, and the RHA 2 indication spans upper face, periorbital, midface and perioral areas rather than one treatment objective.
Can RHA 2 be used in the lips?
Yes. Lips including the philtrum are named in the instructions for use, with a recommended maximum of 2 mL for that indication. Teoxane describes placement in the subdermis or submucosa of the red lip.
How long do results last?
Teoxane gives an estimated lifetime of 12 to 18 months. Duration depends on skin type, the severity of the wrinkle treated, the injection area, the volume placed, and the patient’s physiology and lifestyle.
Which needle is supplied, and can a cannula be used?
Two sterile 30G 1/2″ needles per syringe. A blunt 25G cannula may be used as an alternative; Teoxane has verified compatibility with the TSK 25G/50 mm.
Composition
- Hyaluronic Acid (23 mg/ml)
- Phosphate Buffer pH 7.3
Contains
- 2 × 1 ml pre-filled syringes
- 2 × sterile 30G½” needles
- Package insert
- Traceability labels
TEOSYAL® RHA2
2x1ml
Order in the next 12 hours 2 minutes to ship today
Shipping from 8.12$
Ask our staff about this product
For professional use only. Purchase confirms appropriate training and qualifications
TEOSYAL RHA 2 2x1ml - 23 mg/mL cross-linked hyaluronic acid with 0.3% lidocaine
TEOSYAL RHA 2 is a CE-marked Class III injectable manufactured by Teoxane. It belongs to the dermal filler class: a cross-linked hyaluronic acid gel that corrects by occupying volume, and is progressively resorbed. The full Teosyal range is stocked alongside it.
Placement is not fixed to one plane. Teoxane names the dermis, the subcutaneous layer, the supraperiosteum, and the subdermis or submucosa of the red lip, chosen according to the area being treated. That is why a single product carries an indication spanning the upper face, the periorbital region, the midface and the perioral area.
Choose RHA 2 when the objective is correction across expressive areas rather than projection in one of them, and when the same syringe needs to serve forehead, nasolabial fold and perioral work in a single session.
Product overview
| Mode of correction | Volume replacement by a cross-linked hyaluronic acid gel; biodegradable, progressively resorbed |
|---|---|
| Manufacturer indication | Correction of facial wrinkles and skin creases and augmentation of facial tissue volume, across the upper face, periorbital, midface and perioral regions |
| Placement | Dermis, subcutaneous, supraperiosteal, or subdermis and submucosa of the red lips, depending on the area |
| Onset | Immediate; the gel occupies volume on placement |
| Estimated duration | 12 to 18 months, per Teoxane; dependent on skin type, area, volume placed and patient physiology |
| Patient profile | Adults with wrinkles and creases in mobile facial areas |
Specification
| Product type | Cross-linked hyaluronic acid dermal filler; sterile, transparent, non-pyrogenic viscoelastic injectable gel |
|---|---|
| Manufacturer | Teoxane SA |
| Regulatory status | CE-marked Class III medical device |
| Active substance | Hyaluronic acid, 23 mg/mL, non-animal origin, mean molecular weight above 1 million Dalton |
| Crosslinking | BDDE; degree of crosslinking below 5% by NMR; residual BDDE below 1 ppm |
| Anaesthetic | Lidocaine hydrochloride, 0.3% by mass |
| Buffer | Phosphate buffer pH 7.3 |
| Storage | 2 to 25 degrees Celsius, away from direct sunlight |
| Intended users | Trained healthcare professionals qualified or accredited under national law |
How it works
Hyaluronic acid is a constituent of the dermal extracellular matrix whose content falls with age. RHA 2 replaces volume mechanically: the gel occupies space at the plane where it is placed, corrects wrinkles and cutaneous depressions, and is progressively resorbed. Teoxane reports an aesthetic improvement of the treated area in 70 to 100% of patients across its clinical study programme, and patient-reported satisfaction consistently above 70% up to six months after the first injection.
One syringe, four planes of placement. The region decides the depth, not the product.
Treatment areas
| Region | Areas named in the instructions for use |
|---|---|
| Upper face | Forehead lines, forehead depression, glabellar lines, temples |
| Periorbital | Eyebrows, crow's feet |
| Midface | Nasolabial folds, smile lines and accordion lines |
| Perioral | Perioral rhytids, lips including the philtrum, marionette lines, oral commissures |
Volume per point and per session follows the instructions for use. Teoxane states a maximum of 6 mL per session, and recommends the smallest workable volume in sensitive indications, with a maximum of 2 mL for the lips.
Other fillers indexed for the same objectives: moderate wrinkles, furrows and folds, perioral area.
Administration
Each syringe is supplied with two sterile 30G 1/2" needles from Teoxane-approved suppliers. A blunt 25G cannula may be used instead; Teoxane has verified compatibility with the TSK 25G/50 mm cannula, with an entry point made using a sharp needle of appropriate size. Compatible cannulas and needles are stocked separately. The instructions for use warn against contact between TEOSYAL gels and quaternary ammonium salts such as benzalkonium chloride.
Safety profile
Common reactions at the injection site (at or above 1 in 100), usually mild and self-resolving: pain, tenderness, erythema, bruising, oedema, induration, papules and itching. Less common (between 1 in 1,000 and 1 in 100): discoloration, inflammatory reactions, infection, temporary loss of sensitivity or paraesthesia, allergic reactions, nodules and implant migration.
Injection into or close to a blood vessel may lead to embolisation, vascular occlusion, ischaemia and skin or tissue necrosis. Teoxane reports that although such events are extremely rare, the most serious cases of vascular occlusion may cause temporary or permanent vision impairment, or cerebral ischaemia or haemorrhage leading to stroke, which can be fatal. That risk is higher when injecting in the nose or the glabella - relevant here, because glabellar lines are among the stated indications. If skin whitening, marbling, pain or numbness occurs at any point during the procedure, the injection is stopped.
The product contains lidocaine, which may produce a positive result in a doping test.
Contraindications
- Cutaneous disorders, inflammation or infection at or near the treatment site
- Known hypersensitivity to hyaluronic acid, or a history of severe allergy or anaphylactic shock
- Autoimmune disease
- Pregnancy, breastfeeding, or patients under 18
- Known hypersensitivity to lidocaine or amide local anaesthetics
- Cardiac disease, or treatment for cardiac disease with beta blockers
- Hepatocellular insufficiency or treatment for liver disease
- Epilepsy or porphyria
Teoxane also states that the product is not to be injected into the epidermis, into or close to a blood vessel or nerve, or at depths other than those described in the dosage section, and is not to be combined with peeling, laser or ultrasound-based procedures. This summary does not replace the product-specific instructions for use.
Frequently asked questions
How does RHA 2 differ from TEOSYAL PureSense gels?
By crosslinking degree and by breadth of indication. Teoxane states below 5% crosslinking for RHA 2 against below 10% for the PureSense range, and the RHA 2 indication spans upper face, periorbital, midface and perioral areas rather than one treatment objective.
Can RHA 2 be used in the lips?
Yes. Lips including the philtrum are named in the instructions for use, with a recommended maximum of 2 mL for that indication. Teoxane describes placement in the subdermis or submucosa of the red lip.
How long do results last?
Teoxane gives an estimated lifetime of 12 to 18 months. Duration depends on skin type, the severity of the wrinkle treated, the injection area, the volume placed, and the patient's physiology and lifestyle.
Which needle is supplied, and can a cannula be used?
Two sterile 30G 1/2" needles per syringe. A blunt 25G cannula may be used as an alternative; Teoxane has verified compatibility with the TSK 25G/50 mm.
Composition
- Hyaluronic Acid (23 mg/ml)
- Phosphate Buffer pH 7.3
Contains
- 2 × 1 ml pre-filled syringes
- 2 × sterile 30G½” needles
- Package insert
- Traceability labels
You might be also interested in:
